GSDME and Cholestatic liver disease: Caspase-3 inhibitors, such as Ac-DMPD/DMLD-CMK, effectively block gasdermin E (GSDME)-mediated pyroptosis, suggesting potential therapeutic applications in cholestatic liver disease [92].